Orris

What are the, uh, clinical studies and, uh, random controlled, uh, trials for the use of melatonin for, uh, sleep health, and, uh, what are the side effects of using melatonin?

Reading File
Reading File
Searching PubMed

"melatonin"[MeSH Terms] AND "sleep"[MeSH Terms]

Searching PubMed

"melatonin"[MeSH Terms] AND "sleep"[MeSH Terms]

Searching PubMed

melatonin adverse effects safety

Finding Sources
Searching the Web

melatonin sleep randomized controlled trials meta-analysis side effects guideline

Reading Article

PMID: 38888087

Reading Article

PMID: 34923676

Reading Article

PMID: 37434463

Reading Article

PMID: 41481289

Reading Article

PMID: 33417003

Melatonin has modest, mostly short-term benefit for sleep, and it is generally well tolerated. Evidence is strongest for sleep onset and circadian problems and weakest for chronic insomnia. Long-term safety data are thin.

Key trials and meta-analyses

Dose and timing (adults and healthy volunteers). A 2024 dose-response meta-analysis pooled 26 double-blind RCTs (1,689 observations) in people with insomnia and in healthy volunteers.
  • Melatonin shortened sleep onset latency and increased total sleep time, with the effect peaking at about 4 mg/day.
  • Taking it about 3 hours before desired bedtime worked better than the usual practice of 2 mg 30 minutes before bed.
  • Insomnia status and the interval between dose and sleep predicted the effect on sleep latency.
Insomnia disorder in adults. A 2023 meta-analysis covered 22 studies and 4,875 participants, and compared melatonin and ramelteon with placebo.
  • Prolonged-release melatonin gave small to medium gains over placebo: about 6 minutes shorter subjective sleep latency, 5 minutes shorter objective latency, and 1.9% better sleep efficiency.
  • Effects were larger in people aged 55 or older (sleep efficiency up about 3%).
  • Ramelteon, a melatonin receptor agonist, had larger effects on total sleep time.
  • The authors describe the overall level of evidence as low.
Sleep quality across conditions. A meta-analysis of 23 RCTs found melatonin improved Pittsburgh Sleep Quality Index scores by 1.24 points on average, but heterogeneity was high (I² about 81%).
  • The benefit was seen with respiratory disease, metabolic disorders and primary sleep disorders.
  • It was not seen with psychiatric or neurodegenerative disease.
Children. A 2026 JAMA Network Open systematic review looked at melatonin in children aged 0 to 6.
  • Trials in young children with neurologic conditions such as autism showed improved sleep onset with few adverse events.
  • There are no efficacy data for typically developing children.
  • Prescribing and overdoses have risen sharply, and melatonin is a leading cause of unsupervised medication exposure in young children.
  • A separate 2023 meta-analysis addressed melatonin for sleep disorders in autism. I did not read its abstract.
Recent individual RCTs.
I only saw titles and metadata for these four, not results, so I can't say what they found.
Guidelines. From a secondary web summary I did not verify against the source, the American Academy of Sleep Medicine (AASM) gives a weak recommendation against melatonin for chronic insomnia in adults. Circadian uses such as jet lag and delayed sleep phase are better supported. The textbook Adams and Victor's Principles of Neurology (section "Treatment of Insomnia") agrees that melatonin has a short half-life and a weak hypnotic effect. It is best suited to sleep rhythm disturbances, taken 3 to 4 hours before sleep.

Side effects

Common and usually mild. Katzung's Basic and Clinical Pharmacology (section "Adverse Effects") describes melatonin as well tolerated, with few adverse effects. The reported ones are:
  • next-day drowsiness
  • fatigue
  • dizziness
  • headache
Miller's Anesthesia (section on ICU sleep disturbances) adds nausea and hypotension.
Meta-analytic safety data.
  • A 2022 systematic review of high-dose melatonin (10 mg or more, 79 RCTs, 3,861 adults) found no detectable increase in serious adverse events or in withdrawals due to adverse events.
  • Drowsiness, headache and dizziness were more common, with a rate ratio of 1.40 (95% CI 1.15 to 1.69).
  • 37% of these studies did not report adverse events at all, and the confidence limits were wide.
  • A web-retrieved meta-analysis in REM sleep behavior disorder, which I did not verify, also found no significant difference in side effect rates versus placebo.
Limits of the evidence and cautions.
  • Most trials last 4 weeks or less, so long-term safety is not well established.
  • Over-the-counter products vary in actual melatonin content and are not tightly regulated. I did not look this up in this session, but it is a well-known concern.
  • Children, especially under 6, are at risk of accidental overdose.
  • Melatonin has not been well studied in pregnancy and breastfeeding, in people with seizure disorders, or in people on anticoagulants or immunosuppressants. Check with a clinician in these groups.
  • Melatonin is not a substitute for cognitive behavioral therapy for insomnia (CBT-I), which remains first-line for chronic insomnia.
I can pull the full text of any of these papers, or look at a specific population such as children, older adults or shift workers, if you want.
This is a shared conversation. Sign in to Orris to start your own chat.